摘要
目的 探讨血清神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)、糖类抗原125(CA125)检测对肺癌患者125I粒子植入术后短期疗效的预测价值.方法 选择2020年4月至2022年12月我院收治的86例肺癌患者,均行125I粒子植入术,比较患者治疗前后血清NSE、CEA、CA125水平,评估疗效,对比不同疗效患者血清NSE、CEA、CA125水平,影响疗效的多因素采用Logistic回归分析.结果 治疗后,患者血清NSE、CEA、CA125水平低于治疗前(P＜0.05).治疗有效组血清NSE、CEA、CA125水平低于治疗无效组(P＜0.05).NSE、CEA、CA125均为肺癌患者125I粒子植入术治疗无效的独立危险因素(OR＞1,P＜0.05).结论 血清NSE、CEA、CA125水平是125I粒子植入术治疗肺癌患者疗效的影响因素,可用于短期疗效预测.
Abstract
Objective To explore the predictive value of serum neuron specific enolase(NSE),carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)for short-term efficacy after 125I implantation in patients with lung cancer.Methods 86 patients with lung cancer admitted to our hospital from April 2024 to December 2022 were selected and given 125I implantation.The serum NSE,CEA and CA125 levels before and after treatment were compared,and the efficacy was evaluated.The serum NSE,CEA and CA125 levels of patients with different efficacy were compared,and Logistic regression analysis was used to analyze the multiple factors that affected efficacy.Results After treatment,the serum NSE,CEA,and CA125 levels of patients were lower than those before treatment(P＜0.05).The serum NSE,CEA,and CA125 levels of the effective group were lower than those of the ineffective group(P＜0.05).NSE,CEA and CA125 were independent risk factors for ineffective 125I implantation in patients with lung cancer(OR＞1,P＜0.05).Conclusions Serum NSE,CEA and CA1 25 levels are influencing factors for the effiicacy of 125I implantation in the treatment of patients with lung cancer,which can be used for short-term efficacy prediction.
国家科技期刊平台
NSTL
万方数据